Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial.

We show that long-term CBD treatment had an acceptable safety profile and led to sustained, clinically meaningful reductions in seizure frequency in patients with treatment-resistant DS.